Akero Therapeutics (AKRO) Stock Forecast & Price Target

Compare

650 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AKRO Analyst Ratings

Moderate Buy

3 Buy

7 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Akero

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AKRO Stock 12 Month Forecast

Average Price Target

$60.22

▲(11.77% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Akero Therapeutics in the last 3 months. The average price target is $60.22 with a high forecast of $84.00 and a low forecast of $54.00. The average price target represents a 11.77% change from the last price of $53.88.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","34":"$34","51":"$51","68":"$68","85":"$85"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":84,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$84.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$60.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$54.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,34,51,68,85],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.55,49.43076923076923,52.31153846153846,55.19230769230769,58.073076923076925,60.95384615384616,63.83461538461538,66.71538461538461,69.59615384615384,72.47692307692307,75.3576923076923,78.23846153846154,81.11923076923077,{"y":84,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.55,47.60153846153846,48.653076923076924,49.70461538461538,50.75615384615384,51.80769230769231,52.85923076923077,53.91076923076923,54.96230769230769,56.01384615384615,57.065384615384616,58.11692307692307,59.16846153846154,{"y":60.22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.55,47.12307692307692,47.69615384615384,48.26923076923077,48.84230769230769,49.41538461538461,49.988461538461536,50.56153846153846,51.13461538461539,51.707692307692305,52.28076923076923,52.85384615384615,53.426923076923075,{"y":54,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.82,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.33,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.01,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.82,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.08,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.64,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.31,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.37,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.44,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$84.00

Average Price Target$60.22

Lowest Price Target$54.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrew Fein

H.C. Wainwright

$72→$54

Hold

0.22%

Upside

Downgraded

10/10/25

Akero Therapeutics downgraded to Neutral from Buy at H.C. WainwrightAkero Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

Ritu Baral

TD Cowen

$76→$58

Hold

7.65%

Upside

Downgraded

10/10/25

Hold Rating on Akero Therapeutics Amid NOVO Acquisition and Regulatory UncertaintiesWe believe NOVO is a logical acquirer. We are downgrading to Hold and decreasing our PT to $58 based on deal terms of $54/share in cash plus the NPV of the CVR. We model a 2029 approval (80% POS) for F4 MASH.

Edward Nash

Canaccord Genuity

$73→$54

Hold

0.22%

Upside

Downgraded

10/09/25

Akero Therapeutics downgraded to Hold from Buy at CanaccordAkero Therapeutics downgraded to Hold from Buy at Canaccord

Rami Katkhuda

LifeSci Capital

$57→$58

Hold

7.65%

Upside

Assigned

10/09/25

Cautious Hold Rating on Akero Therapeutics Amid Novo Nordisk Acquisition and Regulatory Uncertainties

Andy Chen

Wolfe Research

―

Hold

―

Downgraded

10/09/25

Akero Therapeutics downgraded to Peer Perform from Outperform at Wolfe ResearchAkero Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research

Andrew Tsai

Jefferies

$56

Hold

3.93%

Upside

Downgraded

10/09/25

Cautious Hold Rating on Akero Therapeutics Amid Acquisition Interest and Uncertainties in Efruxifermin's Clinical Trajectory

Kaveri Pohlman

Clear Street

$49→$54

Hold

0.22%

Upside

Downgraded

10/09/25

Analysts Conflicted on These Healthcare Names: Akero Therapeutics (NASDAQ: AKRO) and HealthStream (NASDAQ: HSTM)

Michael Ulz

Morgan Stanley

$84

Buy

55.90%

Upside

Reiterated

09/18/25

Analysts Are Bullish on These Healthcare Stocks: Scholar Rock Holding (SRRK), Akero Therapeutics (AKRO)We believe the deal provides positive readthrough to Akero's EFX highlighting further interest in the FGF21 mechanism as a target for treating MASH. 11:51 AM GMTM Update 2 M Inc (AKRO.O) Our PT is derived from a discounted cash flow (DCF) analysis, including risk-adjusted revenues for EFX in NASH that assumes a 12.5% discount rate and a 0% terminal growth rate. Risks to Upside n Better than expected clinical data.

Jason Zemansky

Bank of America Securities

$64

Buy

18.78%

Upside

Reiterated

08/25/25

Akero Therapeutics (AKRO) Receives a Buy from Bank of America Securities

Michael DiFiore

Evercore ISI

$60

Buy

11.36%

Upside

Initiated

08/22/25

Evercore ISI Sticks to Their Buy Rating for Akero Therapeutics (AKRO)

Eric Joseph

J.P. Morgan

$69→$68

Buy

26.21%

Upside

Reiterated

05/14/25

Analysts Are Bullish on Top Healthcare Stocks: Akero Therapeutics (AKRO), BioCardia (BCDA)

Ed Arce

Westpark Capital

$72→$75

Buy

39.20%

Upside

Reiterated

02/28/25

Promising Developments and Strong Financial Position Support Buy Rating for Akero Therapeutics

Jonathan Woo

Phillip Securities

$80

Buy

48.48%

Upside

Reiterated

02/28/25

Analysts Offer Insights on Healthcare Companies: Akero Therapeutics (NASDAQ: AKRO), Immunovant (NASDAQ: IMVT) and 4D Molecular Therapeutics (NASDAQ: FDMT)

Eliana Merle

UBS

$42→$109

Buy

102.30%

Upside

Reiterated

01/31/25

Akero Therapeutics price target raised to $109 from $42 at UBSAkero Therapeutics price target raised to $109 from $42 at UBS

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrew Fein

H.C. Wainwright

$72→$54

Hold

0.22%

Upside

Downgraded

10/10/25

Akero Therapeutics downgraded to Neutral from Buy at H.C. WainwrightAkero Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

Ritu Baral

TD Cowen

$76→$58

Hold

7.65%

Upside

Downgraded

10/10/25

Edward Nash

Canaccord Genuity

$73→$54

Hold

0.22%

Upside

Downgraded

10/09/25

Akero Therapeutics downgraded to Hold from Buy at CanaccordAkero Therapeutics downgraded to Hold from Buy at Canaccord

Rami Katkhuda

LifeSci Capital

$57→$58

Hold

7.65%

Upside

Assigned

10/09/25

Cautious Hold Rating on Akero Therapeutics Amid Novo Nordisk Acquisition and Regulatory Uncertainties

Andy Chen

Wolfe Research

―

Hold

―

Downgraded

10/09/25

Akero Therapeutics downgraded to Peer Perform from Outperform at Wolfe ResearchAkero Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research

Andrew Tsai

Jefferies

$56

Hold

3.93%

Upside

Downgraded

10/09/25

Cautious Hold Rating on Akero Therapeutics Amid Acquisition Interest and Uncertainties in Efruxifermin's Clinical Trajectory

Kaveri Pohlman

Clear Street

$49→$54

Hold

0.22%

Upside

Downgraded

10/09/25

Analysts Conflicted on These Healthcare Names: Akero Therapeutics (NASDAQ: AKRO) and HealthStream (NASDAQ: HSTM)

Michael Ulz

Morgan Stanley

$84

Buy

55.90%

Upside

Reiterated

09/18/25

Jason Zemansky

Bank of America Securities

$64

Buy

18.78%

Upside

Reiterated

08/25/25

Akero Therapeutics (AKRO) Receives a Buy from Bank of America Securities

Michael DiFiore

Evercore ISI

$60

Buy

11.36%

Upside

Initiated

08/22/25

Evercore ISI Sticks to Their Buy Rating for Akero Therapeutics (AKRO)

Eric Joseph

J.P. Morgan

$69→$68

Buy

26.21%

Upside

Reiterated

05/14/25

Analysts Are Bullish on Top Healthcare Stocks: Akero Therapeutics (AKRO), BioCardia (BCDA)

Ed Arce

Westpark Capital

$72→$75

Buy

39.20%

Upside

Reiterated

02/28/25

Promising Developments and Strong Financial Position Support Buy Rating for Akero Therapeutics

Jonathan Woo

Phillip Securities

$80

Buy

48.48%

Upside

Reiterated

02/28/25

Analysts Offer Insights on Healthcare Companies: Akero Therapeutics (NASDAQ: AKRO), Immunovant (NASDAQ: IMVT) and 4D Molecular Therapeutics (NASDAQ: FDMT)

Eliana Merle

UBS

$42→$109

Buy

102.30%

Upside

Reiterated

01/31/25

Akero Therapeutics price target raised to $109 from $42 at UBSAkero Therapeutics price target raised to $109 from $42 at UBS

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Akero Therapeutics

1 Month

xxx

Success Rate

8/10 ratings generated profit

Average Return

+12.25%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +12.25% per trade.

3 Months

xxx

Success Rate

13/21 ratings generated profit

Average Return

+13.44%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.90% of your transactions generating a profit, with an average return of +13.44% per trade.

1 Year

Ed ArceWestpark Capital

Success Rate

13/21 ratings generated profit

Average Return

+55.52%

reiterated a buy rating 8 months ago

Copying Ed Arce's trades and holding each position for 1 Year would result in 61.90% of your transactions generating a profit, with an average return of +55.52% per trade.

2 Years

xxx

Success Rate

12/15 ratings generated profit

Average Return

+42.70%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +42.70% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AKRO Analyst Recommendation Trends

Rating

Apr 25

May 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AKRO has received 12 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. AKRO average Analyst price target in the past 3 months is 60.22.

Each month's total comprises the sum of three months' worth of ratings.

AKRO Financial Forecast

AKRO Earnings Forecast

Next quarter’s earnings estimate for AKRO is -$0.93 with a range of -$1.00 to -$0.88. The previous quarter’s EPS was -$0.86. AKRO beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year AKRO has Preformed in-line its overall industry.

No data currently available

AKRO Sales Forecast

Next quarter’s sales forecast for AKRO is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AKRO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year AKRO has Preformed in-line its overall industry.

AKRO Stock Forecast FAQ

What is AKRO’s average 12-month price target, according to analysts?

Based on analyst ratings, Akero Therapeutics Inc’s 12-month average price target is 60.22.

What is AKRO’s upside potential, based on the analysts’ average price target?

Akero Therapeutics Inc has 11.77% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AKRO a Buy, Sell or Hold?

Akero Therapeutics Inc has a consensus rating of Moderate Buy which is based on 3 buy ratings, 7 hold ratings and 0 sell ratings.

What is Akero Therapeutics Inc’s price target?

The average price target for Akero Therapeutics Inc is 60.22. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $84.00 ,the lowest forecast is $54.00. The average price target represents 11.77% Increase from the current price of $53.88.

What do analysts say about Akero Therapeutics Inc?

Akero Therapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of AKRO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Akero Therapeutics (AKRO) Stock Forecast & Price Target

AKRO Analyst Ratings

AKRO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Akero Therapeutics

AKRO Analyst Recommendation Trends

AKRO Financial Forecast

AKRO Earnings Forecast

AKRO Sales Forecast

AKRO Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts